Drug Pricing
Commentary
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
Sally C. Pipes
January 13, 2026
Blog
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Sally C. Pipes
December 31, 2025
Commentary
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
Sally C. Pipes
December 26, 2025
Blog
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
Sally C. Pipes
December 24, 2025
Blog
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...
Sally C. Pipes
December 17, 2025
Commentary
The real story behind Trump’s GLP-1 price cut: Markets still rule
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx. Lilly and ...
Sally C. Pipes
December 15, 2025
Commentary
Why reforming PBMs is the key to lowering drug costs
If lawmakers want to make pharmaceuticals more affordable, they should look past populist policies like price controls that will only make matters worse and set their sights on reforming the Pharmacy Benefit Manager market. PBMs manage the drug benefits for insurers and negotiate discounts with drug manufacturers. You probably use ...
Wayne H Winegarden
December 12, 2025
Commentary
How Competition Drives Healthcare Innovation & Affordability
Making healthcare more affordable requires reforms that strengthen competitive markets, as I outlined in a recent Pacific Research Institute1 paper. Unfortunately, as we’re seeing in California and elsewhere, the trend in government is away from competition and toward fewer choices, hurting patients and increasing costs. When applied to other industries, ...
Wayne H Winegarden
December 10, 2025
Blog
How did the US become the world’s center of pharmaceutical innovation?
What kinds of policies helped the US surpass Great Britain to become the world’s center of pharmaceutical innovation? I think it was a combination of shrewd reforms on the part of the United States, and self-destructive reforms on the part of Europe and other developed nations. In the 1970s, Europe ...
Sally C. Pipes
December 10, 2025
Commentary
Trade Policy Is The Right Way To Fight Foreign Freeloading
Last week, the United States and the United Kingdom announced a trade deal that will require Britain’s National Health Service to pay more for novel prescription drugs in exchange for a reprieve of at least three years from tariffs on its pharmaceutical exports. It’s a perfect example of how the ...
Sally C. Pipes
December 8, 2025
Congress Must Prioritize Patients, Not Insurers, In Renewed Healthcare Debate
Congress has returned to Washington. Democrats are renewing their call to extend COVID-era health insurance subsidies to shield people from hefty premium increases. Just last week, some Republicans in the House joined them to pass a bill that extends these subsidies—putting the question squarely before the Senate. That approach would ...
How can we make drugs more affordable without sacrificing future cures?
How can we make drugs more affordable without sacrificing future cures? To a large extent, the current system works fairly well already to make most of the drugs that Americans take affordable. And that’s because of our robust generics market. Around 90% of prescriptions filled each year are for generics ...
Terrible Effects of Medicare Price Controls Are Here
Medicare will impose price controls on prescription drugs for the first time when the calendar flips to January. Even before those controls formally take effect, the damage is already being done. The scheme has begun to hollow out America’s biomedical research ecosystem. Patients will pay the price — in the ...
Do price controls affect which drugs patients have access to and how soon?
Do price controls affect which drugs patients have access to and how soon? They absolutely do. Just look at the situation in Europe. For years, drug companies have been choosing to withhold certain medicines from European markets rather than accept the price constraints imposed by governments there. As a result, ...
How do price controls damage innovation?
What role do intellectual property laws play in encouraging innovation? They are absolutely essential. IP protections like patents reward those who succeed in creating new medicines and ushering them through the regulatory approval process. They do this by guaranteeing that the IP rights holder behind a new drug will have ...
The real story behind Trump’s GLP-1 price cut: Markets still rule
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 weight-loss drugs dispensed through Medicare and Medicaid. Both firms have also agreed to sell the drugs at lower prices on Trump’s yet-to-be-developed online marketplace for prescription drugs, TrumpRx. Lilly and ...
Why reforming PBMs is the key to lowering drug costs
If lawmakers want to make pharmaceuticals more affordable, they should look past populist policies like price controls that will only make matters worse and set their sights on reforming the Pharmacy Benefit Manager market. PBMs manage the drug benefits for insurers and negotiate discounts with drug manufacturers. You probably use ...
How Competition Drives Healthcare Innovation & Affordability
Making healthcare more affordable requires reforms that strengthen competitive markets, as I outlined in a recent Pacific Research Institute1 paper. Unfortunately, as we’re seeing in California and elsewhere, the trend in government is away from competition and toward fewer choices, hurting patients and increasing costs. When applied to other industries, ...
How did the US become the world’s center of pharmaceutical innovation?
What kinds of policies helped the US surpass Great Britain to become the world’s center of pharmaceutical innovation? I think it was a combination of shrewd reforms on the part of the United States, and self-destructive reforms on the part of Europe and other developed nations. In the 1970s, Europe ...
Trade Policy Is The Right Way To Fight Foreign Freeloading
Last week, the United States and the United Kingdom announced a trade deal that will require Britain’s National Health Service to pay more for novel prescription drugs in exchange for a reprieve of at least three years from tariffs on its pharmaceutical exports. It’s a perfect example of how the ...
